Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry
José Manuel Ramos, María D. López-Carmona, Lidia Cobos-Palacios, Almudena López‐Sampalo, Manuel Rubio‐Rivas, María Dolores Martín Escalante, Santiago de Cossio, M.L. Taboada-Martínez, Antonio Muiño-Míguez, Maria Areses-Manrique, Carmen Martinez-Cilleros, Carlota Tuñón-de-Almeida, Lucy Abella-Vázquez, Angel-Luís Martínez-Gonzalez, Luis-Felipe Díez-García, Carlos-Jorge Ripper, Víctor Asensi, Angeles Martinez-Pascual, Pablo Guisado‐Vasco, Carlos Lumbreras, Ricardo Gómez-Huelgas, on behalf of the SEMI-COVID-19 Network
Abstract
(1) Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29−0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22−0.61) (p < 0.001)). (4) Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19.